文献速递垂体与肾上腺疾病

联合激素替代治疗对绝经后女性醛固酮/肾素比值的影响

Effect of Combined Hormonal Replacement Therapy on the Aldosterone/Renin Ratio in Postmenopausal Women.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

本研究纳入15名血压正常、健康的绝经后女性,在基线和联合激素替代治疗(结合雌激素0.625 mg与甲羟孕酮2.5 mg每日)2周和6周后测量血浆醛固酮、直接肾素浓度(DRC)、血浆肾素活性(PRA)等。联合激素替代治疗显著升高醛固酮和PRA、降低DRC,导致以DRC计算的ARR显著升高,6周时3例超过切点值70;以PRA计算的ARR无显著变化。

要点

  • 联合激素替代治疗可显著升高以DRC计算的ARR,6周时3例超过切点值70。
  • 以PRA计算的ARR在治疗前后无显著变化(P=0.282)。
  • 使用DRC(而非PRA)计算ARR时,联合激素替代治疗有假阳性风险。

核心结论

  • 本研究所用联合口服激素替代治疗可显著升高ARR,仅在以DRC(而非PRA)计算比值时存在原发性醛固酮增多症筛查假阳性风险。

研究设计与样本

  • 研究纳入15名血压正常、健康的绝经后女性,在基线及联合激素替代治疗(结合雌激素0.625 mg与甲羟孕酮2.5 mg每日)2周和6周后于坐位、上午中段测量血浆醛固酮、DRC、PRA、电解质、肌酐及尿醛固酮、皮质醇、电解质、肌酐。

主要发现

  • 联合激素替代治疗与醛固酮升高相关:基线150(85至600)pmol/L,2周230(129至790)pmol/L,6周434(200至1200)pmol/L,P<0.001(Friedman检验)。
  • 联合激素替代治疗与PRA升高相关:基线2.3(1.2至4.3)ng/mL/h,2周3.8(1.4至7.0)ng/mL/h,6周5.1(1.4至10.8)ng/mL/h,P<0.001。
  • 联合激素替代治疗与DRC降低相关:基线21(10至31)mU/L,2周21(10至39)mU/L,6周14(8.0至30)mU/L,P<0.01。
  • 以DRC计算的ARR升高:基线7.8(3.6至34.8),2周11.4(5.4至48.5),6周30.4(10.5至90.2),P<0.001;6周时3例超过切点值70。
  • 以PRA计算的ARR无显著变化:基线79(26至184),2周91(23至166),6周88(50至230),P=0.282;血浆电解质、肌酐及任何尿液测量指标均无显著变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plasma aldosterone/renin ratio (ARR) is the most popular screening test for primary aldosteronism (PA). Because both estrogen and progesterone (including in oral contraceptive agents) affect aldosterone and renin levels, we studied the effects of combined hormonal replacement therapy (HRT) on ARR; renin was measured as both direct renin concentration (DRC) and plasma renin activity (PRA). METHODS: Fifteen normotensive, healthy postmenopausal women underwent measurement (seated, midmorning) of plasma aldosterone, DRC, PRA, electrolytes, and creatinine and urinary aldosterone, cortisol, electrolytes, and creatinine at baseline and after 2 weeks and 6 weeks of treatment with combined HRT (conjugated estrogens 0.625 mg and medroxyprogesterone 2.5 mg daily). RESULTS: Combined HRT was associated with statistically significant increases in aldosterone [median (range): baseline, 150 (85 to 600); 2 weeks, 230 (129 to 790); 6 weeks, 434 (200 to 1200) pmol/L; P < 0.001 (Friedman test)] and PRA [2.3 (1.2 to 4.3), 3.8 (1.4 to 7.0), 5.1 (1.4 to 10.8) ng/mL/h, respectively; P < 0.001] but decreases in DRC [21 (10 to 31), 21 (10 to 39), and 14 (8.0 to 30) mU/L, respectively; P < 0.01], leading to increases in ARR calculated by DRC [7.8 (3.6 to 34.8), 11.4 (5.4 to 48.5), and 30.4 (10.5 to 90.2), respectively; P < 0.001]. The ARR calculated by DRC exceeded the cutoff value (70) in three patients after 6 weeks. There were no significant changes in ARR calculated by PRA [79 (26 to 184), 91 (23 to 166), and 88 (50 to 230), respectively; P = 0.282], plasma electrolytes and creatinine, or any urinary measurements. CONCLUSION: The combined oral HRT used in this study is capable of significantly increasing ARR with a risk of false-positive results during screening for PA but only if DRC (and not PRA) is used to calculate the ratio.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ahmed AH, Gordon RD, Ward G, et al. Effect of Combined Hormonal Replacement Therapy on the Aldosterone/Renin Ratio in Postmenopausal Women. J Clin Endocrinol Metab. 2017. PMID: 28379474. doi:10.1210/jc.2016-3851

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。